{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:41:07Z","timestamp":1777934467046,"version":"3.51.4"},"reference-count":35,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The aim of this study was to assess the safety profiles of two biosimilar medicines (rituximab and trastuzumab) in the treatment of cancer patients within a Portuguese oncology hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This hospital-based prospective observational study followed a cohort event monitoring approach focused on signalling suspected adverse drug reactions (ADRs). Patients undergoing treatment with rituximab biosimilar CT-P10 (Truxima\u00ae) or trastuzumab biosimilar CT-P6 (Herzuma\u00ae) were recruited over an 11-month and a 6-month period, respectively. Clinicians identified eligible patients and used paper-based forms to report all ADRs associated with biosimilar medicines. ADR case reports were assessed for seriousness, expectedness and causality in the Pharmacovigilance Unit of Coimbra.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety-four patients received biosimilar medicines (rituximab, n\u2009=\u200935; trastuzumab, n\u2009=\u200959). Of those, 4 patients (11.4%) experienced 16 ADRs with rituximab and 1 patient (1.7%) experienced 5 ADRs with trastuzumab. All case reports contained serious and expected ADRs that were at least probably related with biosimilar medicines under study. Based on the MedDRA PT coding, the most reported ADR for rituximab CT-P10 was chest discomfort (n\u2009=\u20094; 19.1%), followed by odynophagia (n\u2009=\u20092; 9.5%). Trastuzumab CT-P6 was associated with back pain, headache, pain in extremity, tachypnoea and tremor (each, n\u2009=\u20091; 4.8%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results of this study suggest that using biosimilar rituximab and biosimilar trastuzumab to treat cancer patients in the real-world clinical setting is associated with acceptable safety profiles. No new safety problems were identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220957079","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T14:30:44Z","timestamp":1600266644000},"page":"1432-1438","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-world intensive safety monitoring of biosimilars rituximab and trastuzumab in a Portuguese oncology hospital"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-8717","authenticated-orcid":false,"given":"Diogo","family":"Mendes","sequence":"first","affiliation":[{"name":"UFC \u2013 Coimbra Regional Pharmacovigilance Unit, CHAD \u2013 Centre for Health Technology Assessment and Drug Research, AIBILI \u2013 Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal"},{"name":"Drug Safety and Effectiveness Research Network, Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1291-7302","authenticated-orcid":false,"given":"Joana","family":"Abrantes","sequence":"additional","affiliation":[{"name":"UFC \u2013 Coimbra Regional Pharmacovigilance Unit, CHAD \u2013 Centre for Health Technology Assessment and Drug Research, AIBILI \u2013 Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal"},{"name":"Drug Safety and Effectiveness Research Network, Coimbra, Portugal"}]},{"given":"Gra\u00e7a","family":"Rigueiro","sequence":"additional","affiliation":[{"name":"Drug Safety and Effectiveness Research Network, Coimbra, Portugal"},{"name":"IPO-C \u2013 Instituto Portugu\u00eas de Oncologia de Coimbra Francisco Gentil, E.P.E., Coimbra, Portugal"}]},{"given":"Ana Filipa","family":"Pais","sequence":"additional","affiliation":[{"name":"Drug Safety and Effectiveness Research Network, Coimbra, Portugal"},{"name":"IPO-C \u2013 Instituto Portugu\u00eas de Oncologia de Coimbra Francisco Gentil, E.P.E., Coimbra, Portugal"}]},{"given":"Ana","family":"Penedones","sequence":"additional","affiliation":[{"name":"UFC \u2013 Coimbra Regional Pharmacovigilance Unit, CHAD \u2013 Centre for Health Technology Assessment and Drug Research, AIBILI \u2013 Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal"},{"name":"Drug Safety and Effectiveness Research Network, Coimbra, Portugal"}]},{"given":"Carlos","family":"Alves","sequence":"additional","affiliation":[{"name":"UFC \u2013 Coimbra Regional Pharmacovigilance Unit, CHAD \u2013 Centre for Health Technology Assessment and Drug Research, AIBILI \u2013 Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal"},{"name":"Drug Safety and Effectiveness Research Network, Coimbra, Portugal"},{"name":"Laboratory of Social Pharmacy and Public Health, School of Pharmacy, University of Coimbra, Coimbra, Portugal"}]},{"given":"Francisco","family":"Batel-Marques","sequence":"additional","affiliation":[{"name":"UFC \u2013 Coimbra Regional Pharmacovigilance Unit, CHAD \u2013 Centre for Health Technology Assessment and Drug Research, AIBILI \u2013 Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal"},{"name":"Drug Safety and Effectiveness Research Network, Coimbra, Portugal"},{"name":"Laboratory of Social Pharmacy and Public Health, School of Pharmacy, University of Coimbra, Coimbra, Portugal"}]}],"member":"179","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"bibr1-1078155220957079","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0153"},{"key":"bibr2-1078155220957079","first-page":"2559","volume":"34","author":"Mian M","year":"2014","journal-title":"Anticancer Res"},{"key":"bibr3-1078155220957079","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0648-2"},{"key":"bibr4-1078155220957079","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.04.003"},{"key":"bibr5-1078155220957079","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02953"},{"key":"bibr6-1078155220957079","unstructured":"European Medicines Agency. Biosimilar medicines: overview, www.ema.europa.eu\/en\/human-regulatory\/overview\/biosimilar-medicines-overview (accessed 1 April 2020)."},{"key":"bibr7-1078155220957079","unstructured":"European Medicines Agency. ICH Q5E Biotechnological\/biological products subject to changes in their manufacturing process: comparability of biotechnological\/biological products, www.ema.europa.eu\/en\/ich-q5e-biotechnologicalbiological-products-subject-changes-their-manufacturing-process (2005, accessed 1 April 2020)."},{"key":"bibr8-1078155220957079","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0881-y"},{"key":"bibr9-1078155220957079","doi-asserted-by":"crossref","unstructured":"Barbier L, Ebbers HC, Declerck P, et al. The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review.\n                      Clin Pharmacol Ther\n                      2020. Epub ahead of print. DOI: 10.1002\/cpt.1836.","DOI":"10.1002\/cpt.1836"},{"key":"bibr10-1078155220957079","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-016-0300-z"},{"key":"bibr11-1078155220957079","unstructured":"KPMG Advisory N.V - Commissioned by Medicines for Europe. www.medicinesforeurope.com\/wp-content\/uploads\/2019\/10\/20190903_Hospital-Reform-Study_final.pdf (2019, accessed 1 April 2020)."},{"key":"bibr12-1078155220957079","unstructured":"Resolu\u00e7\u00e3o do Conselho de Ministros n\u00b0 56\/2016. Di\u00e1rio da Rep\u00fablica: I s\u00e9rie, No 197, www.dre.pt\/application\/conteudo\/75521164 (2016, accessed 1 April 2020)."},{"key":"bibr13-1078155220957079","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0431-5"},{"key":"bibr14-1078155220957079","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0244-3"},{"key":"bibr15-1078155220957079","unstructured":"Instituto Portugu\u00eas de Oncologia Francisco Gentil E.P.E. Humaniza\u00e7\u00e3o dos Cuidados de Sa\u00fade Prestados ao Doente Oncol\u00f3gico, www.ipocoimbrafg.files.wordpress.com\/2019\/12\/info-dezembro-2019-final.pdf (2019, accessed 1 April 2020)."},{"key":"bibr16-1078155220957079","unstructured":"Instituto Portugu\u00eas de Oncologia Francisco Gentil E.P.E Relat\u00f3rio anual sobre o acesso a cuidados de sa\u00fade, www.ipocoimbrafg.files.wordpress.com\/2020\/04\/relatc3b3rio-sobre-o-acesso-a-cuidados-de-sac3bade-2019.pdf (2019, accessed 1 April 2020)."},{"key":"bibr17-1078155220957079","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219849277"},{"key":"bibr18-1078155220957079","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) \u2013 annex I \u2013 definitions (Rev. 4), www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf (2017, accessed 1 April 2020)."},{"key":"bibr19-1078155220957079","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP)-Module VI \u2013 Collection, management and submission of reports of suspectedNadverse reactions to medicinal products (Rev 2), www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf (2017, accessed 1 April 2020)."},{"key":"bibr20-1078155220957079","unstructured":"European Medicines Agency. Assessment report \u2013 Truxima, International non-proprietary name: rituximab, www.ema.europa.eu\/en\/documents\/assessment-report\/truxima-epar-public-assessment-report_en.pdf (2017, accessed 1 April 2020)."},{"key":"bibr21-1078155220957079","unstructured":"European Medicines Agency. Assessment report \u2013 Herzuma, International non-proprietary name: trastuzumab, www.ema.europa.eu\/en\/documents\/assessment-report\/herzuma-epar-public-assessment-report_en.pdf (2018, accessed 1 April 2020)."},{"key":"bibr22-1078155220957079","unstructured":"MedDRA. Medical Dictionary for Regulatory Activities website. Welcome to MedDRA, www.meddra.org\/how-to-use\/basics\/hierarchy (accessed 1 April 2020)."},{"key":"bibr23-1078155220957079","unstructured":"The Uppsala monitoring Centre. The use of WHO-UMC system for standardised case causality assessment, www.who-umc.org\/media\/164200\/who-umc-causality-assessment_new-logo.pdf (accessed 1 April 2020)."},{"key":"bibr24-1078155220957079","unstructured":"European Medicines Agency. Signal management, www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/pharmacovigilance\/signal-management (accessed 1 April 2020)."},{"key":"bibr25-1078155220957079","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0210-0"},{"key":"bibr26-1078155220957079","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1633632"},{"key":"bibr27-1078155220957079","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2693"},{"key":"bibr28-1078155220957079","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30157-1"},{"key":"bibr29-1078155220957079","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00398-7"},{"key":"bibr30-1078155220957079","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00376-z"},{"key":"bibr31-1078155220957079","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30434-5"},{"key":"bibr32-1078155220957079","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.18305"},{"key":"bibr33-1078155220957079","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2017.74.0126","volume":"36","author":"Pivot X","year":"2018","journal-title":"J Clin Oncol"},{"key":"bibr34-1078155220957079","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-018-0706-9"},{"key":"bibr35-1078155220957079","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-012-0014-6"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220957079","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220957079","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220957079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:23:43Z","timestamp":1777688623000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220957079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1177\/1078155220957079"],"URL":"https:\/\/doi.org\/10.1177\/1078155220957079","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,16]]}}}